PTO/SB/30 (07-09)

Approved for use through 0773 12 C. ONE 065 1-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Passenwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a useful OMB control number.

Request	Application Number	10/519,871
for	Filing Date	10/31/2005
Continued Examination (RCE) Transmittal	First Named Inventor	Hans-Jurgen Weidemann
Address to:	Art Unit	3652
Mail Stop RCE Commissioner for Patents	Examiner Name	James Keenan
P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket Number	SOLFZ.P11
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.		
 Submission required under 37 CFR 1.114 Note if the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instruction entered, applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). 		
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.		
Consider the arguments in the Appeal Brief or Reply Brief previously filed on		
li. U Other		
b. Laclosed		
I Amendment/Reply iii, Information Disclosure Statement (IDS)		
ii. Affidavit(s)/ Declaration(s) iv. Other Substitute Amendment		
2. Miscellaneous		
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a a. period of months, (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)		
b. Other		
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 100100.		
I. CE fee required under 37 CFR 1.17(e)		
ii. 📝 Extension of time fee (37 CFR 1.138 and 1.17)		
iii. Other		
b. Check in the amount of \$enclosed		
c. Payment by credit card (Form PTO-2038 enclosed)		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
SIGNATURE OF APPLICA	NT, ATTORNEY, OR AGENT RE	
Signature Name (Print/Type) Myron Greenspan	Date Regi	01/07/2010 stration No. 25,680
	F MAILING OR TRANSMISSION	20,000
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope		
addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.		
Signature Name (Print/Type)		

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including generating, preparing, and submitting the completed application from the USPTO more will vary depending upon the individual good and application from the USPTO. There will vary depending upon the individual good recommendation of the USPTO. There will vary depending upon the individual good recommendation of the USPTO. There will vary depending upon the individual good recommendation of the USPTO. the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and The You proper the Chief Information Officer, U.S. Patient and The Young the Chief Information Officer, U.S. Patient and The Young t